ESC 2020: Randomized Trial Confirms ACEI/ARB Safety for Patients with COVID-19
EDITORS' NOTE: This story was updated January 19, 2021 when the study was published in Journal of the American Medical Association.
ESC 2020: DCRI Successfully Conducts Trial in FDA-Catalyst and Sentinel System
The IMPACT-AFib trial lays the groundwork for future large-scale trials to be conducted using electronic claims data.
ESC 2020: ADAPTABLE Presents Opportunities, Underscores Challenges for Pragmatic Research
DCRI Executive Director Adrian Hernandez, MD, MHS, called for a platform that will enable clinical research to be embedded into patient care, allowing research to be conducted at patients’ homes.
ESC 2020: DCRI Analysis Sheds New Light on Management of Ischemic Heart Disease and Heart Failure
The ISCHEMIA trial made headlines last year at the American Heart Association 2019 Scientific Sessions, where primary results were presented indicating that invasive heart procedures may not reduce
DCRI Think Tank Outlines Opportunities to Improve Drug Development for Kidney Disease
CARRA Registry Fills Gap in Pediatric Rheumatology
Reliance on Observational Data Could Hinder Discovery of Evidence-Based Treatments
Even in the midst of a global pandemic, taking the time to conduct randomized controlled trials is the most rigorous way to build evidence for potential treatments, according to a recent opinion pi
Combining Randomization with Real-World Data to Move Research Forward
As the proliferation of real-world data continues, it is important to refocus on combining randomized trials with real-world data sources rather than relying on observations or common sense, write